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This study reviewed the lipid proﬁle of human immunodeﬁciency virus/acquired immuno-
deﬁciency syndrome (HIV/AIDS) patients in relation to use of antiretroviral therapy (ART),
and its different classes of drugs. A total of 190 articles published in peer-reviewed journals
were  retrieved from PubMed and LILACS databases; 88 of them met  the selection crite-
ria  and were included in the review. Patients with HIV/AIDS without ART presented an
increase of triglycerides and decreases of total cholesterol, low density lipoprotein (LDL-c),
and  high density lipoprotein (HDL-c) levels. Distinct ART regimens appear to promote differ-
ent  alterations in lipid metabolism. Protease inhibitors, particularly indinavir and lopinavir,
were  commonly associated with hypercholesterolemia, high LDL-c, low HDL-c, and hyper-
triglyceridemia. The protease inhibitor atazanavir is apparently associated with a more
advantageous lipid proﬁle. Some nucleoside reverse-transcriptase inhibitors (didanosine,
stavudine, and zidovudine) induced lipoatrophy and hypertriglyceridemia, whereas aba-
cavir increased the risk of cardiovascular diseases even in the absence of apparent lipid
disorders, and tenofovir resulted in lower levels of cholesterol and triglycerides. Although
non-nucleoside reverse-transcriptase inhibitors predisposed to hypertriglyceridemia and
hypercholesterolemia, nevirapine was particularly associated with high HDL-c levels, a
protective factor against cardiovascular diseases. Therefore, the infection itself, different
classes of drugs, and some drugs from the same class of ART appear to exert distinct
alterations in lipid metabolism.
©  2013  Elsevier  Editora  Ltda.  
Perﬁl  lipídico  de  pacientes  infectados  pelo  HIV  em  relac¸ão à  terapia
antirretroviral:  uma  revisão
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Este estudo faz uma revisão sobre o perﬁl lipídico de pacientes com vírus da imunodeﬁ-
ciência humana/síndrome da imunodeﬁciência adquirida (HIV/AIDS) em relac¸ão ao uso da
terapia antirretroviral (TARV), e suas diferentes classes de fármacos. Um total de 190 artigos
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publicados em revistas indexadas foram selecionados das bases de dados PubMed e LILACS;
88  deles preencheram os critérios de selec¸ão e foram incluídos nesta revisão. Pacientes
com HIV/AIDS sem uso de TARV apresentaram aumento de triglicérides e diminuic¸ão
dos  níveis de colesterol total, lipoproteína de baixa densidade (LDL-c) e lipoproteína de
alta densidade (HDL-c). Distintos regimes de TARV promoveram diferentes alterac¸ões no
metabolismo lipídico. Inibidores de protease, particularmente indinavir e lopinavir, foram
comumente associados com hipercolesterolemia, aumento de LDL-c, diminuic¸ão de HDL-c
e  hipertrigliceridemia. O inibidor de protease atazanavir aparentemente está associado a
menores alterac¸ões do perﬁl lipídico. Alguns inibidores da transcripitase reversa análogos
de  nucleosídeos (didanosina, estavudina e zidovudina), induziram lipoatroﬁa e hiper-
trigliceridemia, enquanto o abacavir aumentou o risco cardiovascular mesmo na ausência
de  aparentes distúrbios lipídicos, e o tenofovir resultou em menores níveis de colesterol e
triglicérides. Embora os inibidores da transcriptase reversa não análogos de nucleosídeos
possam predispor a hipertrigliceridemia e hipercolesterolemia, a nevirapina, particular-
mente, foi associada a maiores níveis de HDL-c, um fator de protec¸ão contra doenc¸as
cardiovasculares. Portanto, a própria infecc¸ão, diferentes classes de fármacos e alguns
fármacos da mesma classe de TARV podem exercer distintas alterac¸ões no metabolismo
lipídico.
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atients with human immunodeﬁciency virus (HIV)/acquired
mmunodeﬁciency syndrome (AIDS) frequently present alter-
tions in lipid metabolism due to infection with HIV itself,
ncluding elevated serum concentrations of triglycerides and
ow levels of total cholesterol.1 The introduction of antiretro-
iral therapy (ART) in the mid-1990s led to substantial
mprovement in the prognosis of HIV/AIDS patients, with a
eduction in morbidity and mortality due to opportunistic dis-
ases and consequent improvement of the patient’s quality of
ife.2–7
However, there is evidence that ART is associated with
ipodystrophy syndrome, a disturbance of lipid metabolism
haracterized by insulin resistance, dyslipidemia, and fat
aldistribution, usually presenting as visceral abdominal obe-
ity and cervical fat pad accumulation (buffalo hump),2,5,7–9
etabolic bone disease (osteopenia and/or osteoporosis), and
actic acidosis.5,7,10–12
ART-associated dyslipidemia is characterized by elevated
erum concentrations of total cholesterol, triglycerides, low
ensity lipoprotein (LDL-c), very low-density lipoprotein
VLDL), and apolipoprotein B (apoB), and low levels of
igh density lipoprotein (HDL-c), constituting an athero-
enic lipid proﬁle.13,14 This lipid changes occurs within three
onths of initiating ART, and plateau after six to nine
onths.15
The prevalence of dyslipidemia and other risk factors for
ardiovascular disease is signiﬁcant in HIV/AIDS patients
eceiving ART, ranging from 20% to 80% depending on
he study design and population investigated.8 These lipid
lterations were ﬁrst described in patients who used antiretro-
iral regimens containing protease inhibitors, but also were
ater observed in patients who  received regimens consisting
f nucleoside reverse-transcriptase inhibitors (NRTI) and non-
ucleoside reverse-transcriptase inhibitors (NNRTI).16,17
In view of the high prevalence of dyslipidemia and the
ncreased risk for cardiovascular diseases among patientssevier Editora Ltda.    
with HIV/AIDS, which is a matter of concern for public health,
the present review aimed to describe the lipid proﬁle of HIV-
infected patients in relation to use of ART, and its different
classes of drugs.
Methods
The PubMed (US National Library of Medicine, National Insti-
tutes of Health) and LILACS (Literatura Latino-Americana e do
Caribe) databases were searched without restrictions on pub-
lication year or study design until August 2011. The keywords
“HIV” [MESH] OR “Acquired Immunodeﬁciency Syndrome”
[MESH] AND “Dyslipidemias” [MESH] were used for search in
the PubMed database, and 169 articles were retrieved. The
LILACS database was searched using “HIV and Dislipidemia”,
and 21 articles were retrieved. Thus, 190 articles were ﬁrst
selected, but one article appeared in both databases; therefore,
189 articles were selected for this review.
All studies investigating the association between lipid
alterations in HIV/AIDS patients with or without treatment
were identiﬁed and included in the review. Case report articles
(12 articles from PubMed), articles related to lipid-lowering
drugs (8 articles from PubMed), articles whose full text could
not be accessed (35 articles from PubMed and ﬁve from
LILACS), and articles not focusing on lipid alterations in
HIV/AIDS patients (39 articles from PubMed and nine from
LILACS) were excluded. 75 articles were thus selected from the
PubMed database and six articles from the LILACS database.
In addition, seven studies were identiﬁed in the references
of these articles and retrieved for relevance, considering that
the articles were useful to describe the possible metabolic
mechanisms to explain the lipid alterations of the patients.
Therefore, a total of 88 articles were included in the review
(Fig. 1).
Este é um artigo Open Access sob a licença de CC BY-NC-NDAll the 88 articles were discussed in this review.
Tables 1 and 3 presented the results of the original articles
(n = 51) included in this search, excluding previously published
reviews.
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PubMed
LILACS
Keywords: “HIV” [MESH] or “Acquired
Immunodefcency Syndrome” [MESH] and
“Dyslipidemias” [MESH] = 169 articles were
retrieved.
Keywords: “HIV and dislipidemia” = 21 articles
were retrieved.
75 articles
Total = 88
articles were
included in
the review.
6 articles
+ 7 articles
Excluded were articles involving:Excluded were articles involving:
• Case reports (12);
• Articles related to lipid-lowering
drugs (8);
• Articles whose full text could not be
accessed (35);
• Articles not focusing on lipid
alterations in HIV/AIDS patients
(39).
• Articles whose full text could not be
accessed (5);
• Articles not focusing on lipid
alterations in HIV/AIDS patients (9).
searcFig. 1 – Re
Results  and  discussion
HIV/AIDS  and  lipid  alterations
Lipid alterations in patients with HIV/AIDS caused by the
infection itself had been reported before the implementation
of ART.1,13 In this respect, serum triglyceride concentrations
were higher and the levels of total cholesterol, LDL-c and
HDL-c were lower in HIV-seropositive patients receiving no
ART when compared to uninfected controls.1,18,19 These alter-
ations were detected in patients infected with different HIV-1
subtypes.19
Low serum concentrations of HDL-c can be used as a
marker of chronic inﬂammatory activity.20 In a cohort study
conducted in Spain, untreated HIV-infected patients pre-
sented low HDL-c levels, especially if they had already received
antiretroviral therapy in the past.21 However, HDL-c levels
were found to be low even in patients receiving ART presenting
adequate viral suppression and immune reconstitution, a
ﬁnding that suggests that inﬂammatory activity was not com-
pletely controlled.20
Table 1 summarizes the results of the original studies (n = 3)
that assessed the lipid proﬁle of HIV/AIDS patients without
ART.Possible  metabolic  mechanisms
Factors that contribute to dyslipidemia in HIV infection
are altered cytokine proﬁle, decreased lipid clearance, and
increased hepatic synthesis of VLDL.23h design.
Cytokines such as tumor necrosis factor alpha (TNF-)
and interleukin-6 (IL-6) appear to promote lipid peroxidation,
besides endothelial and platelet activation, and the produc-
tion of reactive oxygen species.14
An increase in serum triglyceride concentrations is
observed in HIV-infected patients as the disease progresses,
particularly in the presence of opportunistic infections, possi-
bly due to an increase in the levels of inﬂammatory cytokines
(TNF- , interleukins, and interferon alpha [IFN- ])22,24 and
steroid hormones.1,18 The lower the CD4+ T lymphocyte
count in peripheral blood, the higher the concentrations of
triglycerides and the lower the levels of total cholesterol and
LDL-c.1,18 In contrast, low concentrations of HDL-c are found
in HIV-infected patients, regardless of the CD4+ T lymphocyte
count.18,25
HIV/AIDS,  ART,  and  lipid  alterations
Changes in lipid metabolism associated with ART use have
been commonly reported in all age groups of HIV-infected
patients.5–7
In relation to the metabolic side effects of ART, children are
more vulnerable than adults because of their status as growing
organisms and their longer exposure to ART.5
Cross-sectional studies with HIV-infected children and
adolescents receiving ART have shown high frequency
26–28of dyslipidemia, lipodystrophy, retinol, and b-carotene
deﬁciencies27 and, therefore, high risk for cardiovascular
diseases.28 In a multicenter study, HIV-infected children
with symptoms of fat redistribution presented adiponectin
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Table 1 – Studies assessing the lipid proﬁle of patients with HIV/AIDS without ART.
Reference Study design and treatment
duration
Lipid  proﬁle alterations
Fourie et al.
(2010)19
Sub-study from PURE
HIV+ (n = 300) versus HIV−
(n = 300): 12 years
-  HIV+ versus HIV-: ↓HDL-c (1.23 versus 1.7 mmol/L); ↓LDL-c (2.6 versus
2.8 mmol/L); ↑TG (1.29 versus 1.15 mmol/L), ↑CRP (3.31 versus 2.13 mg/L); ↑IL-6 (4.7
versus 3.72 pg/L)
- HIV-1 subtype C was associated with dyslipidemia
Grunfeld et al.
(1991)22
AIDS (n = 45); HIV+ (without
AIDS; n = 13); HIV−
(controls; n = 17)
-  AIDS: ↑IFN- (p < 0.001 compared to controls); with detectable levels in 84%
of AIDS patients
- HIV+: three of 13 had detectable IFN-
- AIDS and HIV+: signiﬁcant correlation between IFN- and TG (R = 0.44, p < 0.002)
IFN- modulated lipid metabolism, and was probably responsible for the
hypertriglyceridemia found in AIDS patients
Grunfeld et al.
(1989)1
AIDS (n = 32); HIV+ (n = 8);
HIV− (controls; n = 17)
-  AIDS versus controls: ↑TG and prevalence of hypertriglyceridemia (50%)
(p < 0.002 and p < 0.005, respectively)
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AART, antiretroviral therapy; CRP, C-reactive protein; HDL-c, high dens
lipoprotein; PURE, Prospective Urban and Rural Epidemiological stud
ecrease, associated with insulin resistance, increase of
riglycerides and reduction of HDL-c.29
Pregnancy already is a condition that is characterized by
mportant metabolic changes. The use of ART during preg-
ancy is associated with several concerns, which include
otential teratogenicity, risk for the exposed and uninfected
ewborn, possible reduced efﬁcacy of antiretroviral regimens
n this particular condition, and safety considerations for the
other, including potentially increased risk of speciﬁc adverse
vents.6
HIV-infected older adults have a slower immunological
esponse to ART and a higher risk for cardiovascular diseases,
onsidering the factors: aging, HIV infection, and ART.7 A mul-
icenter cross-sectional study involving 179 elderly individuals
ndicated that 54% had dyslipidemia, 23% had cardiovascular
iseases, and 58% had lipodystrophy.30
Six classes of antiretroviral drugs are currently available
Table 2).
Protease inhibitors, NRTIs, and NNRTIs are the drugs most
requently associated with lipodystrophy and alterations in
ipid metabolism.32,33 Furthermore, the drugs of each class
23xert distinct metabolic effects.
Table 3 summarizes the results of the original studies
n = 48) that assessed the lipid proﬁle of HIV/AIDS patients with
RT.
Table 2 – Antiretroviral drugs by class.*
PI NRTI NNRTI 
Atazanavir (ATV)
Darunavir (DRV)
Fosamprenavir (FPV)
Indinavir (IDV)
Lopinavir (LPV)
Nelﬁnavir (NFV)
Ritonavir (RTV)
Saquinavir (SQV)
Tipranavir (TPV)
Abacavir (ABC)
Didanosine (ddI)
Emtricitabine (FTC)
Stavudine (d4T)
Lamivudine (3TC)
Tenofovir (TDF)
Zidovudine (AZT)
Efavirenz (EFV
Etravirine (ET
Nevirapine (N
PI, protease inhibitors; NRTI, nucleoside reverse-transcriptase inhibitors;
inhibitor.
∗ Guidelines for the use of antiretroviral agents in HIV-1-infected adults anoprotein; IFN-,  interferon-alpha; IL, interleukin; LDL-c, low density
 triglycerides.
Protease  inhibitors
Elevated plasma lipid concentrations were observed in 70%
to 80% of patients who received ART containing pro-
tease inhibitors. This class of antiretroviral drugs has been
associated with the development of peripheral lipodys-
trophy, central adiposity, breast hypertrophy, and insulin
resistance.66,72–76
Patients who use protease inhibitors for a long period of
time frequently present hypertriglyceridemia, elevated con-
centrations of LDL-c, reduced HDL-c levels, and accumulation
of apolipoprotein E and apolipoprotein CIII (apoCIII).66,67,69,77
However, the reduction of HIV-1 viral load has been associated
with an increase of serum HDL-c.69
In the ﬁrst exploratory studies, various protease inhibitors
(saquinavir, indinavir, nelﬁnavir, and ritonavir) were associ-
ated with different degrees of hyperlipidemia.71,78 However,
some authors found that dyslipidemic patients using pro-
tease inhibitors who switched to atazanavir-containing
regimens showed improvement of lipid parameters, while the
immunological and virological efﬁcacy of the regimen was
maintained.36,42,53,79–81In a multicenter, prospective, observational study of 23,437
HIV-infected patients conducted by the Data Collection on
Adverse Events of Anti-HIV Drugs (DAD) Study Group (2007), an
association was initially observed between the use of protease
FI CCR5 antagonist Integrase inhibitor
)
R)
VP)
Enfuvirtide
(T-20)
Maraviroc
(MVC)
Raltegravir  (RAL)
 NNRTI, non-nucleoside reverse-transcriptase inhibitors; FI, fusion
d adolescents.31
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Table 3 – Studies assessing the lipid proﬁle of patients with HIV/AIDS receiving ART.
Reference Type of ART Study design and treatment duration Lipid proﬁle alterations
Podzamczer et al.
(2011)34
NVP versus ATZ/RTV, both
combined with TDF + FTC
(ARTEN Study)
Prospective study (n = 569): baseline evaluation
up to 48 weeks
-  NVP promoted ↑ TC, ↑HDL-c, ↑LDL-c, and ↑apoA1, but not of apoB; ATZ/r was
associated with ↑ TG; NVP versus ATZ/r: < TC/HDL-c ratio and < apoB/apoA ratio;
- Low Framingham score in the two groups
MacInnes et al.
(2011)35
MVC versus EFV Intervention study: MVC (n = 360) versus EFV
(n = 361), both combined with AZT/3TC
for 96 weeks
-  For patients with TC and LDL-c below the NCEP treatment thresholds at the beginning
of the study (TC: 35% × 11% in the EFV group versus LDL-c: 23% × 8% in the MVC group)
(p < 0.001)
- For patients exceeding the NCEP thresholds: TC: 83% × 50% (p = 0.008); LDL-c: 86% ×
55% (p = 0.03); HDL-c: 43% × 62% (p = 0.002) (values referring to an increase for patients
with HDL-c < 40 mg/dL)
Lu et al. (2011)36 Two NRTI +ATV 1×/day
or ATV/r 1×/day
Prospective observational study (n = 66):
48 weeks
-  ATV regimen was well tolerated and resulted in signiﬁcant improvement of
hyperlipidemia
Crane et al.
(2011)37
Comparison between NRTI
pairs used in the ﬁrst ART
Cohort study (n = 2,267): patients with at least
two months of ART
-  TDF/3TC or TDF/FTC associated with ↓ lipid levels (TC, TG, HDL-c, LDL-c and
non-HDL-c); ddI/3TC associated with ↑ LDL-c; d4T/3TC with ↑TG; ddI/d4T with ↑ HDL-c
Adewole et al.
(2010)25
NNRTI Cross-sectional study (n = 130): 12 months - NNRTI containing NVP promoted ↑ HDL-c and stabilization of TC and TG
Battistini et al.
(2010)27
ART Cross-sectional study with children and
adolescents (n = 30): median duration with ART:
28.4 months
-  Lipodystrophy: 53.3%
- Dyslipidemia (AIDS versus controls): 60% versus 23% (p = 0.004)
- ↑ Frequency of dyslipidemia, lipodystrophy, and retinol and b-carotene deﬁciencies,
but it was not possible to demonstrate a correlation of these ﬁndings with lipid
peroxidation
Randell et al.
(2010)38
TDF/3TC + FPV/RTV versus
TDF/3TC + LPV/RTV
Intervention study (n = 27): 2×/day
Pharmacokinetics was evaluated up
to two weeks
-  ↑ 6.6% TC with FPV and 10.9% with LPV. Similar changes in lipids and lipoprotein
subfractions in the groups with ↑ TG, ↑VLDL, ↑chylomicrons and ↑LDL-c. No signiﬁcant
alteration in HDL-c and ↓ small-HDL-c
Palios et al.
(2010)39
HAART versus untreated Cross-sectional study (n = 40) - Patients on HAART presented ↑ TC compared to control
Nguemaïm et al.
(2010)18
ART Case-control study [HIV+ (n = 172) and HIV−
(n = 172)]
HIV+  versus HIV- subjects:
- CD4 < 50 cells/L: ↓TC and ↓LDL-c (p < 0.0001); ↑TG (p < 0.001); > TC/HDL-c ratio
(p < 0.01); > HDL-c/LDL-c ratio (p = 0.02)
- CD4 50–199 cells/L: ↓TC (p < 0.001) and ↑TG (p < 0.001)
- CD4 200–350 cells/L: ↑TG (p = 0.003); > TC/HDL-c (p < 0.0002); > HDL-c/LDL-c ratio
(p = 0.04)
- CD4 >350 cells/L: > TC/HDL-c ratio (p < 0.0001); > HDL-c/LDL-c ratio (p < 0.001)
- HIV+: < HDL-c irrespective of the CD4 cell count.
Tungsiripat et al.
(2010)40
ART with TDF Double-blind, placebo-controlled crossover study
(n = 17): 12 weeks
TDF  versus placebo:
- ↓ non-HDL-c, ↓ LDL-c and ↓TC
- TDF: lipid-lowering action
Werner et al.
(2010)28
HAART Cross-sectional study with children
and adolescents (n = 43): three months
-  Lipid abnormality: 88.3%;
- Body shape change: 13.9%
Bunupuradah
et al. (2009)41
Double-boosted PI
combination, SQV and
LPV/r
n  = 50: 12 weeks (HIV-infected children who had
failed on reverse transcriptase inhibitors)
-  TC and HDL-c ↑signiﬁcantly over time, whereas TG and LDL-c did not
-Body shape changes: Approximately 50%
Calza et al.
(2009)42
First HAART: ABC/3TC +
ATV/RTV versus TDF/FTC +
ATV/RTV
Clinical Trial [ABC/3TC (n=42); TDF/FTC
(n=47)]:48 weeks
-  ABC/3TC + ATV/RTV: higher CD4
- Both groups: ↓ TG. Similar TC and LDL-c
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Reference Type of ART Study design and treatment duration Lipid proﬁle alterations
Carosi et al.
(2009)43
ABC/3TC + FPV/RTV
(1400 mg/100 mg), 1×/day
versus ABC/3TC + FPV/RTV
(700 mg/100 mg), 2×/day
Intervention study (n = 214): follow-up for 24
and 48 weeks
-  No signiﬁcant alteration in non-HDL-c values in either group
Kim et al. (2009)44 Different HAART regimens Single center, retrospective cohort study
(n = 178). (HIV-1 infected children with HAART
versus HIV-1 infected children without
medications [controls])
-  72.4% had TC > 180 mg/dl, 53.4% had TC > 200 mg/dl
- For TC > 200, the multivariable analysis showed ↑ risk with NRTI/NNRTI (HR: 1.86, 95%
CI: 1.34–2.19) and NRTI/PI (HR: 3.45, 95% CI: 2.65–4.51) when compared to controls
Sarni et al.
(2009)26
ART (80% HAART and 30%
with PI)
Cross-sectional study with children
and adolescents (n = 30): median duration
with ART = 28.4 months
-  Lipodystrophy: 53.3%
- Dyslipidemia: 60%
- Children on HAART with PI: > % of mixed lipodystrophy
Tao et al. (2009)45 Comparison of patients on
HAART with and without
lipodystrophy
Cross-sectional study (n = 52) -  Prevalence of hypercholesterolemia, hypertriglyceridemia, and low HDL-c levels:
17.3%, 50.0%, and 17.3%, respectively
- Patients with lipodystrophy: ↑ TG and ↓ HDL-c
Mothe et al.
(2009)30
HAART Multicenter cross-sectional study with
HIV-1-infected population aged 70 years or more
(n = 179)
-  Dyslipidemia: 54%
-Cardiovascular disease: 23%
-Lipodystrophy: 58%
Williams et al.
(2009)46
ART Prospective observational study (n = 433):
patients received ART for a mean of eight years
-  28% hypercholesterolemia
- Patients receiving RTV or NNRTI (especially EFV) presented ↑ TC and TG
Estrada and
Fuster (2008)47
TDF+FTC+DRV/RTV versus
TDF+FTC+LPV/RTV
Intervention study: 48 weeks (ARTEMIS) - Similar virological and immunological response. DRV/RTV was associated with a
↓ frequency of adverse lipid effects
Calza et al.
(2008)48
FPV/RTV versus LPV/RTV. Observational study (n = 82): 18 months - LPV/RTV: ↑ TG
Farhi et al.
(2008)49
HAART Cross-sectional study (n = 235) - 77.5% prevalence of dyslipidemia
Ananworanich
et al. (2008)50
First HAART: two NRTI +
SQV/RTV
Intervention study (n = 272): 24 weeks - ↑ TC, ↑TG, ↑LDL-c, and ↑HDL-c
Pupulin et al.
(2008)51
HAART (68% with PI) Cross-sectional study (n = 60): use of HAART
(mean: ﬁve years)
-  ↑ TC (28%), ↑ HDL-c (83%), and ↑ LDL-c (3%) suggesting an effect of HIV infection
and not of HAART. 21% of patients with hypertriglyceridemia
Domingo et al.
(2008)52
Onset of ART with two NRTI +
EFZ or two NRTI + LPV/RTV
Retrospective cohort (VACH) (n = 1,550):
evaluation at zero to three; three to six; six to 12;
12-18; and >18 months
-  Use of LPV/RTV was associated with higher risk of early hypertriglyceridemia
Bernal et al.
(2008)21
ART (NNRTI and PI) Cross-sectional (n = 219): two months - Prevalence of low HDL-c: 45%
Colaﬁgli et al.
(2008)53
AZT Observational study (n = 197): follow-up
for at least one month
-  AZT: ↓TC, ↓HDL-c, ↓non-HDL-c, and ↓TG. Marked reduction in patients with high
baseline TC and TG values. Decrease of cardiovascular risk
Kosalaraksa et al.
(2008)54
Double boosted PI, SQV
and LPV/r
n=  50: 48-weeks (children who have failed
NNRTI/NRTI- based regimens)
-  ↑ median TC and TG (+ 35 mg/dL; + 37 mg/dL, respectively, p < 0.001)
Tassiopoulos
et al. (2008)55
ART Prospective cohort study (Pediatric AIDS Clinical
Trials Group 219C) (n = 2,122 perinatally
HIV-infected children free of
hypercholesterolemia at entry): six years
- 13% of children had hypercholesterolemia at entry
- + 13% developed hypercholesterolemia during follow-up for an incidence rate
of 3.4 cases per 100 person-years (95% CI: 3.0-3.9)
- After adjustment for age, boosted PI use (HR: 13.9, 95% CI: 6.73-28.6), nonboosted PI
use (HR: 8.65, 95% CI: 4.19-17.9), and NNRTI use (HR: 1.33, 95% CI: 1.04-1.71) were
associated with ↑ risk of hypercholesterolemia, and > viral load was protective (> 50 000
versus ≤ 400 copies/mL; HR: 0.59, 95% CI: 0.39-0.90)
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Reference Type of ART Study design and treatment duration Lipid proﬁle alterations
Aurpibul et al.
(2007)56
HAART (either NVP or EFV,
together with 3TC and d4T)
were prospectively followed
n = 90 (Children): 144 weeks -Central lipohypertrophy: 46%; peripheral lipoatrophy: 20%; and combined type: 34%
-Hypertriglyceridemia: 12%; hypercholesterolemia: 11%
-Low HDL-c decreased from 94% at baseline to 12% at week 144 (p < 0.01)
Llibre et al.
(2006)20
Replacement of d4T
with TDF
Prospective multicenter study (n = 873):
12 months
-  ↓TC, ↓LDL-c and ↓TG. Patients with hyperlipidemia presented marked reduction
in LDL-c and TG. The greatest reduction in TG was observed in patients with severe
hypertriglyceridemia
Kumar et al.
(2006)57
ABC+3TC+AZT
versus AZT+3TC+NFV versus
d4T+3TC+NFV
Intervention study: 96 weeks - ABC+3TC+AZT: lower LDL-c
- TC: ABC+3TC+AZT<AZT+3TC+NFV< d4T+3TC+NF
- No change in HDL-c with any treatment
Castro-Sansores
et al. (2006)58
HAART Cross-sectional study (n = 211) - 44% hyperlipidemia; 20% hypercholesterolemia; 32% hypertriglyceridemia;
14% hypertriglyceridemia + hypercholesterolemia; NRTI: more frequent lipid alterations
De Luca et al.
(2006)59
Onset of ART:
two NRTI + EFV versus two
NRTI + LPV/r
Prospective observational cohort:
2 NRTI + EFV (n = 481); 2 NRTI + LPV/r (n = 193)
-  ART regimens containing EFV or LPV with similar efﬁcacy and tolerability
- LPV was associated with higher rates of hypertriglyceridemia
Floridia et al.
(2006)6
PI and d4T use Observational study with HIV-infected pregnant
women (n = 248)
-  ↑ mean lipid values progressively and signiﬁcantly during pregnancy: 141.6 mg/dL
for TG (p < 0.001), 60.8 mg/dL for TC (p < 0.001), 13.7 mg/dL for HDL-c (p < 0.001),
and 17.8 mg/dL for LDL-c (p = 0.001)
- Women with PI versus without PI (at all trimesters): > mean TG
- d4T: dyslipidemic effect at ﬁrst trimester only
Verkauskiene
et al. (2006)29
HIV-infected children with
ART (in the majority of
children, treatment was
> four years)
Multicenter study (n = 130): December 2000
to April 2002
-  32 children with fat redistribution syndrome: 14 with atrophic lipodystrophy and 18
with hypertrophic lipodystrophy
- ↑ TG and ↓ HDL-c in atrophic lipodystrophy versus no lipodystrophy
- HIV-infected children with symptoms of fat redistribution: ↓adiponectin, associated
with dyslipidemia
Jones et al.
(2005)60
First HAART using different
regimens: two NRTI +
one NNRTI
versus two NRTI + one PI
versus two NRTI + two PI
Prospective longitudinal study (n = 1,664) - d4T and PI associated with hypercholesterolemia
- TDF+3TC+EFV (28 patients) without ↑TC
Keiser et al.
(2005)61
Two NRTI + one PI changing
to two NRTI + ABC versus
maintenance two NRTI +
one PI
Evaluation after 28 weeks: ABC (n = 52) or PI
(n = 52)
-  ABC: ↓ TC, ↓LDL-c, and ↓TG. No difference in HDL-c
Viganò et al.
(2005)62
Patients receiving HAART
containing 3TC, d4T and a
PI were randomized to
switch PI to EFV and d4T
to TDF at baseline (Group 1)
or at week 24 (Group 2)
Prospective evaluation (n = 28: 48-weeks;
HIV-infected children)
-  Group 1: signiﬁcant ↓ in cholesterol (p < 0.05), ↓ HDL-c ratio (p < 0.01), and ↓TG (p <
0.05) was observed 24 and 48 weeks after the switch of HAART
-Group 2: unchanged lipids in 24 weeks prior to the switch of HAART and a signiﬁcant
improvement on cholesterol (p < 0.05), HDL-c ratio (p < 0.01), and TG (p < 0.05) were
observed 24 weeks after the switch of HAART
Lucas et al.
(2003)63
HAART Cohort study (n = 444): ﬁve years - After four years, 35% of the patients with viral suppression developed diabetes
and hyperlipidemia
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Reference Type of ART Study design and treatment duration Lipid proﬁle alterations
Christeff et al.
(2002)64
ART Cross-sectional study (n = 42; 27 of whom had
symptoms of lipodystrophy)
-  ↑IFN- in lipodystrophy-positive versus lipodystrophy-negative and controls
- ↑IFN-:  positive correlation with ↑TC, ↑TG, ↑VLDL, ↑ apoB and >apoB/apoAI ratio
Galli et al.
(2002)65
Two NRTIs Follow-up for three months (n = 335) - 23%: hypertriglyceridemia
- 10.5%: hypercholesterolemia
Fauvel et al.
(2001)66
PI with two NRTIs (most
frequently: IDV with d4T
and 3TC)
Follow-up for three months (n = 60 male) - Carriers of the -455C variant: 30% lower levels of HDL-c than non-carriers. TG↑
according to the number of variant alleles
- Apo C-III polymorphisms: genetic predisposition to develop dyslipidemia under PI
therapy
Rakotoambinina
et al. (2001)67
HAART with PI Cohort (n = 175): 24 months - Lipoatrophy: ↑TG
- Nucleoside analog: risk factor for lipoatrophy
Thiébaut et al.
(2001)68
HAART (PI versus other
HAART combinations)
Prospective cohort (n = 925): 25 months - 70 experienced hypertriglyceridemia; 4.2 cases per 100 person years (CI=3.2 ±5.2)
- Baseline TG level and being overweight were risk factors of hypertriglyceridemia,
together with advanced HIV disease. The contribution of HAART was not demonstrated
Vergis et al.
(2001)69
ART with PI Prospective study (n = 56): one year - ↑TG (> 250 mg/dL): 52%
- Adherence > 80% to a PI versus adherence < 80%: ↑LDL-c (79%); severe ↑TG
(> 800 mg/dL) (21%)
- < Viral load was associated with > HDL-c level
Carr et al.
(1999)70
ART with PI versus ART
without PI
With  PI (n = 113): follow-up mean 21 months
Never treated with PI (n = 45; 28 with follow-up)
-  Lipodystrophy: 83% of PI recipients and 4% of treatment-naïve patients (p = 0.0001)
- < Body fat: independently associated with longer duration of PI therapy and
< bodyweight before therapy, and more severe lipodystrophy was associated with ↑TG
and ↑C-peptide (previous [p < 0.03] and current [p ≤ 0.01], and less peripheral
and greater central fat [p = 0.005 and 0.09; respectively])
- Hyperlipidemia: 74% of treated patients versus 28% of naïve patients (p<0.001)
Schmidt et al.
(1999)71
PI-treated patients versus
control group
Prospective study (n = 98) - 57%: Hyperlipidemia
- PI-treated patients versus control group: LDL-c=146 mg/dL (range: 53-274 mg/dL) versus
105 mg/dL (range: 22-188 mg/dL; p < 0.001); VLDL = .5 mg/dL (5-253 mg/dL) versus
18 mg/dL (range: 3-94 mg/dL; p < .001)
- > Frequency of the apolipoprotein E2 allele and E4 allele: hyperlipidemic subjects
- Patients with excessive hypertriglyceridemia: ↓ lipoprotein lipase activity
- >Lipodystrophy: hyperlipidemic
ABC, abacavir; APV, amprenavir; ART, antiretroviral therapy; ATV, atazanavir; AZT, zidovudine; 95% CI, 95% conﬁdence interval; DRV, darunavir; ddI, didanosine; d4T, stavudine; EFV, efavirenz; ETR,
etravirine; FPV, fosamprenavir; FTC, emtricitabine; HAART, highly active antiretroviral therapy; HR, hazard ratio; HDL-c, high density lipoprotein; IDV, indinavir;IL, interleukin; IFN-,  interferon alpha;
LDL-c, low density lipoprotein; LPV, lopinavir; LPV/r, lopinavir with a booster of ritonavir; MVC, maraviroc; NCEP, National Cholesterol Education Program; NFV, nelﬁnavir; NNRTI, non-nucleoside reverse
transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; RTV, ritonavir; SQV, saquinavir; TC, total cholesterol; TDF, tenofovir; TG, triglycerides;
TNF-, tumor necrosis factor alpha; TPV, tipranavir; 3TC, lamivudine.
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inhibitors and an increased risk of myocardial infarction. How-
ever, this risk was slightly lower after adjustment for lipid
concentrations.82 In a subsequent investigation by the DAD
Study Group, the best model to predict the risk of myocar-
dial infarction derived from a dataset of 22,625 HIV-infected
patients without a history of cardiovascular disease should
include age, gender, systolic blood pressure, smoking status,
family history of cardiovascular diseases, diagnosis of dia-
betes, total cholesterol, HDL-c, time of indinavir and lopinavir
exposure, and current use of abacavir.83
The Pediatric AIDS Clinical Trials Group 219C was the ﬁrst
large prospective cohort study to examine the effect of pro-
tease inhibitors and other antiretroviral medications on the
incidence of hypercholesterolemia among HIV-infected chil-
dren and adolescents. This group indicated that the use of
protease inhibitors leads to a marked increase in total choles-
terol levels.55
Kim et al., in a retrospective cohort study involving HIV-
1 infected children with highly active antiretroviral therapy
(HAART) versus HIV-1 infected children without HAART found
that those using the NRTI/protease inhibitors-regimen pre-
sented signiﬁcantly higher total cholesterol levels than NRTI
and NRTI/NNRTI.44
For children who have failed on reverse transcrip-
tase inhibitors-based regimens, double boosted protease
inhibitors, saquinavir, lopinavir, and ritonavir represents an
option for second line treatment. However, the drugs signiﬁ-
cantly increased the median levels of serum cholesterol and
triglycerides after 48 weeks.54 Bunupuradah et al., in the same
population, showed that, after 12 weeks, total cholesterol and
HDL-c increased signiﬁcantly, whereas triglycerides and LDL-c
did not.41
In an observational study with HIV-infected pregnant
women, there were differences in lipid values at each
trimester by protease inhibitors and stavudine use. HIV-
positive pregnant women using protease inhibitors presented
a progressive increase in triglycerides and cholesterol values
from the ﬁrst to the third trimester.6
Nucleoside  reverse-transcriptase  inhibitors
Antiretroviral treatment regimens containing NRTIs have
also been associated with alterations in body fat deposition,
particularly lipoatrophy, similar to the alterations observed
with protease inhibitor-containing regimens. In addition,
metabolic alterations, particularly changes in serum triglyc-
eride concentrations, are observed.65
However, the alterations in lipid metabolism are less evi-
dent in patients using a combination of tenofovir + lamivudine
compared to those using zidovudine + lamivudine, stavudine +
lamivudine, or didanosine + lamivudine, with the observation
of lower serum concentrations of LDL-c, total cholesterol, and
triglycerides in the former.37,40
The effect of regimens containing tenofovir indicates a
lipid-lowering action of this NRTI and differs from that of
other drugs from the same class of antiretroviral drugs.37,40,53
Replacement of NRTIs such as stavudine with tenofovir might
be a useful strategy to improve the lipid proﬁle of patients
with dyslipidemia, particularly triglyceride levels, with a con-
sequent reduction of cardiovascular risk.20 For HIV-infected
children, switching stavudine to tenofovir is virologically and 0 1 3;5  9(2):186–198
immunologically safe and provides a signiﬁcant improvement
in lipid proﬁle.62
In contrast, the use of the NRTIs abacavir and didanosine
was found to be an independent risk factor for myocar-
dial infarction in the DAD Study.84 Subsequently, the same
group found that current use of abacavir was an independent
risk factor for myocardial infarction above the measurable
metabolic effects of the drug.83
Floridia et al. showed that stavudine was associated with
dyslipidemic effect in HIV-infected pregnant women in the
ﬁrst trimester only.6
Non-nucleoside  reverse-transcriptase  inhibitors
ART regimens containing nevirapine are associated with a bet-
ter lipid proﬁle, mainly because they provide higher serum
concentrations of HDL-c.34,85,86 Bernal et al. observed that an
undetectable viral load and NNRTI regimens containing nevi-
rapine protected against low levels of HDL-c.21
The lipid proﬁle of patients with AIDS and a previous
history of severe immunodepression who achieved immune
reconstitution with ART has been shown to vary according to
the antiretroviral regimen used. Patients treated with protease
inhibitors (booster dose of ritonavir) or efavirenz presented
a signiﬁcant increase of total cholesterol and triglyceride
concentrations, whereas an increase of serum HDL-c levels
was observed in those receiving nevirapine.46 However, for
HIV-infected children, Viganò et al. demonstrated that switch-
ing the protease inhibitor to efavirenz improved the lipid
proﬁle.62
Aurpibul et al. showed that, in HIV-infected children who
began HAART (either nevirapine or efavirenz, together with
lamivudine and stavudine), low HDL-c decreased from 94% at
baseline to 12% at week 144 (p < 0.01); dyslipidemia occurred
only in 11% to 12% of children.56
Possible  metabolic  mechanisms
Protease inhibitors are known to inhibit lipogenesis and
adipocyte differentiation and to stimulate lipolysis of subcu-
taneous fat. NRTIs, in turn, can also reduce lipogenesis and
adipocyte differentiation in subcutaneous tissue and might be
one of the possible causes of mitochondrial toxicity, inhibiting
mitochondrial DNA polymerase , which leads to the deple-
tion of mitochondrial DNA. In addition, antiretroviral drugs
have been shown to increase central visceral fat and the lev-
els of fatty acids in blood, with a further increase of fatty acids
oxidation.23,64
Apparently, HIV/AIDS patients receiving ART who  develop
lipodystrophy have higher serum concentrations of inﬂamma-
tory cytokines (IL-6 and TNF-). In addition, evidence indicates
a relationship between an increase of IFN-  and elevations of
serum concentrations of total cholesterol, triglycerides, VLDL,
apoB, and apoB/apoA1.64 In this respect, protease inhibitors
appear to bind to LDL receptor-related protein (LRP), reducingLRP-lipoprotein lipase complex on vascular endothelium, and
impairing the uptake of remnant hepatic chylomicrons and
VLDL.76,87 Moreover, protease inhibitors may directly stimu-
late hepatic triglyceride synthesis through up-regulation of
s . 2 0 
m
t
a
i
g
o
t
p
t
(
m
t
b
1
e
r
u
p
i
e
o
p
t
d
S
d
e
a
s
f
C
H
a
b
a
A
m
l
h
a
w
(
i
t
r
d
T
v
t
s
m
r
1
1
1
1
1
1
1r e v a s s o c m e d b r a 
RNA  production in hepatic cells for key enzymes involved in
he triglyceride biosynthetic pathway, leading to the hepatic
ccumulation of triglyceride-rich lipoparticles.77
These drugs may also modify lipoprotein metabolism by
nterfering with the expression of inﬂammatory cytokine
enes and oxidative stress-related genes.87 The expression
f genes in adipocytes and hepatocytes is modulated by pro-
ease inhibitors through sterol regulatory element-binding
roteins (SREBPs), cytoplasmic retinoic-acid binding protein
ype 1 (CRABP-1), peroxisome proliferator activated receptors
PPARs), and apoCIII, events that contribute to the develop-
ent of atherogenic dyslipidemia.3
Carr et al. have proposed that the pathogenesis of lipodys-
rophy syndrome is based upon the structural similarity
etween the catalytic region of HIV-1 protease and CRABP-
 and LRP, probably establishing a high afﬁnity among these
lements.76
Protease inhibitor-induced peripheral lipodystrophy is a
esult of impaired CRABP1-mediated cis-9-retinoic acid stim-
lation of retinoid X receptor: PPAR-  and of the capacity of
rotease inhibitors to inhibit cytochrome P450 3A, resulting
n reduced differentiation and increased apoptosis of periph-
ral adipocytes. Hyperlipidemia is exacerbated by inhibition
f LRP, leading to central obesity, breast fat deposition in the
resence of estrogen, insulin resistance, and diabetes mellitus
ype 2.76
Bastard et al. found that protease inhibitors induce altered
ifferentiation status of peripheral adipocytes by altering
REBP1 function in vivo, because this abnormal adipocyte
ifferentiation is associated with greatly reduced SREBP1c
xpression. 88
Nevertheless, the mechanisms that promote lipid alter-
tions in HIV/AIDS patients are still not completely under-
tood, and may be potentiated by genetic and environmental
actors, as well as by medications.23
onclusions
IV-infected patients without ART presented lipid alter-
tions associated with the infection itself, characterized
y a decrease of total cholesterol, LDL-c, and HDL-c,
nd by an increase of triglyceride levels. In contrast,
RT regimens promoted distinct alterations in the lipid
etabolism of these patients. Protease inhibitors, particu-
arly indinavir and lopinavir, were commonly associated with
ypercholesterolemia, hypertriglyceridemia, elevated LDL-c,
nd reduced HDL-c. Fewer lipid alterations were observed
ith use of the protease inhibitor atazanavir. Some NRTIs
didanosine, stavudine, and zidovudine) more  frequently
nduced lipid alterations, particularly lipoatrophy and hyper-
riglyceridemia. However, tenofovir-containing NRTI regimens
esulted in a better metabolic proﬁle. Patients using NNRTIs
eveloped hypertriglyceridemia and hypercholesterolemia.
he NNRTI nevirapine was particularly associated with ele-
ated concentrations of HDL-c. Therefore, the infection itself,
he different classes of drugs, and some drugs from the
ame class of ART appear to exert distinct alterations in lipid
etabolism.
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